Cancer is still a major worldwide health concern that calls for further precision medicine breakthroughs. With a focus on their revolutionary potential in targeted drug delivery and less invasive therapeutic treatments, this study critically investigates the incorporation of nanorobotics into cancer. Nanorobots, which are designed at the nanoscale, provide unmatched medication delivery selectivity, lowering systemic toxicity and improving therapeutic effectiveness. Precise tumor targeting, regulated medication release, and better patient outcomes are made possible by their molecular and cellular interactions. In order to ensure structural integrity and functional optimization, this research examines the manufacturing techniques that are crucial for the creation of nanorobots, such as chemical etching, soft lithography, and thin-film deposition. Furthermore, the differences between inorganic and organic nanobots are examined in terms of toxicity mitigation techniques, efficiency, and biocompatibility. Nanorobotic systems with swarm intelligence, self-replication, and real-time illness monitoring capabilities have been designed thanks to advancements in nanotechnology, establishing them as a ground-breaking area of biomedical engineering. Notwithstanding these encouraging possibilities, issues including exorbitant manufacturing costs, immune response evasion, and long-term safety concerns demand more research. This study integrates knowledge of cancer epidemiology, genetic predispositions, environmental risk factors, and existing therapy constraints to synthesize new research on nanorobotic applications in oncology. Nanorobots are a paradigm change in precision oncology, providing a new method of cancer detection and therapy through improved accuracy, efficiency, and tailored therapeutic approaches by fusing technical innovation with clinical requirement.
Bala et al. (Wed,) studied this question.